Drug Pipeline

Drug Pipeline

The result of nearly a decade of research and development, Trinity scientists have engineered a variety of new nano-scale drug entities, formulating optimal structures for binding previously non-synergistic agents. Trinity's formulation candidates have the potential to be used either as monotherapies or in combination with existing standards of care.

Trinity intends to bring its drug candidates through the FDA regulatory process and enter into strategic relationships with major pharmaceutical companies for territories outside North America. If approved for use, the market potential for Trinity's compounds is significant; as they not only treat acute illness, but also once under control, shift the treatment paradigm to managing chronic diseases with little or no impact on quality of life.